What would you like us to do with the funds you've selected
Growing sales in emerging markets is vital to top line growth of healthcare holdings, say Polar Capital healthcare investors.
By Jonathan Boyd, Editor-in-Chief, Financial Express Thursday April 29, 2010
Latest results from pharmaceutical sector giant AstraZeneca lend further support to the idea that emerging markets are going to become increasingly important for funds focused on the healthcare sector, say Daniel Mahony and Gareth Powell, managers on the Polar Capital healthcare investment team. The drugs maker just reported year-on-year growth of 19 per cent from emerging markets. Mahony and Powell estimate that over the next 10 years emerging markets could add $400bn to $500bn to global pharmaceutical sales; this would be a positive step forward for an industry that recently has seen sales in developed markets suffer from a number of key patents expiring. By 2020 the value of pharmaceutical sales in emerging markets could equal that currently seen in the US and Western Europe. Polar Capital recently announced it is to launch the Polar Capital Global Healthcare Growth and Income Trust, in order to tap into the changes seen occuring in the global healthcare market.
advertisement
Follow FE Trustnet
Gleeson: The fund I’d back to hit a short-term target
GMT 07:00 | 15-May-2013
Gray: Market rally has made me more bearish than ever
GMT 15:30 | 30-Apr-2013
Do you think UK inflation will increase in the next 12 months?
Yes, it will increase significantly
Yes, it will increase slightly
It will stay at around the same level
No, I think inflation will fall
Vote
